Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma

Inclusion Criteria

Concurrent Medication: Required:

• PCP prophylaxis with Bactrim, dapsone, or aerosolized pentamidine.
• Oral candidiasis prophylaxis with fluconazole, ketoconazole, or clotrimazole oral troches.
• Antiretroviral agent available by therapy IND.
• MAI prophylaxis with rifabutin (in patients with CD4 counts < 100 cells/mm3).

Patients must have:

• HIV infection.
• Primary CNS lymphoma with NO systemic involvement.

Prior Medication:

Allowed:

• Prior corticosteroids.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Concomitant malignancy other than Kaposi's sarcoma, curatively treated carcinoma in situ of the cervix, or squamous or basal cell carcinoma of the skin.
• Active uncontrolled infection.
• Renal failure, active nonmalignant duodenal ulcer, uncontrolled diabetes mellitus, or other serious medical conditions that would preclude aggressive cytotoxic chemotherapy administration.
• Active heart disease (congestive heart failure or heart block greater than first degree on EKG).

Concurrent Medication:

Excluded:

• Any investigational agent other than antiretroviral agents available by therapy IND.

Patients with the following prior conditions are excluded:

• No prior malignancy other than Kaposi's sarcoma, curatively treated carcinoma in situ of the cervix, or squamous cell or basal cell carcinoma of the skin.
• No new infectious complications within the past 2 weeks that require a change in antibiotics.
• History of myocardial infarction within the past 3 months.

Prior Medication:

Excluded:

• Prior chemotherapy other than for Kaposi's sarcoma.

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety